scispace - formally typeset
M

Michael E. Pichichero

Researcher at Rochester General Health System

Publications -  134
Citations -  4898

Michael E. Pichichero is an academic researcher from Rochester General Health System. The author has contributed to research in topics: Streptococcus pneumoniae & Otitis. The author has an hindex of 34, co-authored 134 publications receiving 4207 citations. Previous affiliations of Michael E. Pichichero include University of Rochester & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Immune responses in neonates

TL;DR: This review focuses mainly on the developmental and functional mechanisms of the human neonatal immune system and the mechanism of innate and adaptive immunity and the role of neutrophils, antigen presenting cells, differences in subclasses of T lymphocytes (Th1, Th2, Tregs and B cells are discussed.
Journal ArticleDOI

Comparison of 13 Acellular Pertussis Vaccines: Overview and Serologic Response

TL;DR: It is clear that DTaP vaccines can stimulate immune responses that exceed those of licensed whole-cell vaccine with respect to the measured antibodies.
Journal ArticleDOI

Maternal immunization with tetanus–diphtheria–pertussis vaccine: effect on maternal and neonatal serum antibody levels

TL;DR: There was a significant increase in the odds that newborns from mothers who received Tdap during pregnancy have antibodies that may provide protection against diphtheria, pertussis toxin, and fimbriae 2/3.
Journal Article

Comparison of 13 Acellular Pertussis Vaccines: Adverse Reactions

TL;DR: The authors compared the reactogenicity of a licensed conventional whole-cell (WCL) and 13 acellular pertussis vaccines that differed in the source, manufacture, and quantity of included antigens; all vaccines included diphtheria and tetanus toxoids.
Journal ArticleDOI

Comparison of 13 Acellular Pertussis Vaccines: Adverse Reactions

TL;DR: Although there were differences among the acellular vaccines, none was consistently the most or least reactogenic; all were associated with substantially fewer and less severe adverse reactions than a standard commercial whole-cell vaccine.